default author photo

Mingye Zhao

China Pharmaceutical University

Nanjing Medical University

Jiangning

Nanjing, 211166

China

  • China Pharmaceutical University

SCHOLARLY PAPERS

3

DOWNLOADS

167

TOTAL CITATIONS

0

Scholarly Papers (3)

Actions:
Email selected abstracts
1.

Impacts of Systemic Treatments On Health-Related Quality of Life for Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis

Number of pages: 24 Posted: 23 Aug 2023
Yunlin Jiang, Mingye Zhao, Yue Yin, Xue ping Zheng and Wenxi Tang
Nanjing University of Chinese Medicine (NJUCM), China Pharmaceutical University, China Pharmaceutical University, Nanjing University of Chinese Medicine (NJUCM) and China Pharmaceutical University - Center for Pharmacoeconomics and Outcomes Research
Downloads 75 (844,901)

Abstract:

Loading...

Metastatic colorectal cancer, Health-related quality of life, Network meta-analysis, Systematic review, Treatment selection

2.

Economic Burden Attributable to High BMI in China, 1990–2023: A Modelling Study Based on Global Burden of Disease 2023

Number of pages: 34 Posted: 18 Dec 2025
Ruiyi Zhang, Yue Yin, Mingye Zhao, Wenxi Tang and See PDF
Shandong University, China Pharmaceutical University, China Pharmaceutical University, China Pharmaceutical University - Center for Pharmacoeconomics and Outcomes Research and Please see PDF for full list of authors & affiliations
Downloads 57 (1,020,567)

Abstract:

Loading...

High body-mass index, Value of a statistical life, Economic burden, China

3.

Maturity and Longitudinal Evolution of Overall Survival Evidence in Regular FDA Oncology Approvals, 2006–2025

Number of pages: 36 Posted: 01 May 2026
Mingye Zhao, Yue Yin, Taihang Shao, Haoqiao Shao, Yunong Jiang and Wenxi Tang
China Pharmaceutical University, China Pharmaceutical University, The Chinese University of Hong Kong (CUHK), China Pharmaceutical University, China Pharmaceutical University and China Pharmaceutical University
Downloads 35 (1,304,549)

Abstract:

Loading...

FDA regular approval, oncology drugs, evolution of efficacy, maturity, clinical meaningfulness, overall survival